IVIG

What can we help you find?
Differentiating Characteristics and Evaluating Intravenous, Subcutaneous Immunoglobulin
Subcutaneous immunoglobin has increased treatment options for patients with several conditions, such as primary immunodeficiency diseases and chronic inflammatory demyelinating polyneuropathy.
FDA Letter Confirms IG Product Shortage
The report highlighted the reasoning for the drug shortage as well as specific applicants and manufacturers that the agency will be working with to mitigate the supply of Ig products. 
Immunoglobulin Use in Immune Deficiency, Autoimmune Disease States
In a Skidki-na-vse Continuing Education Supplement, Elena E. Perez, MD, PhD, examined the evolution of immunoglobulin [Ig] in its treatment use, including patient populations and potential adverse events.
Novel Hemophilia A Treatment Method Sees Early Success
New approach involves treating patients with a high dose factor VIII concentrates along with emicizumab, a modification of the standard immune tolerance induction.
 
Optimizing Immunoglobulin Use for Immune Disorder Treatment
Specialty pharmacists play an important role in the selection of immunoglobulin G products and optimizing therapy for patients.
Pharmacist Education Is Key to Helping Patients With Chronic Inflammatory Demyelinating Polyneuropathy
At the Asembia Specialty Pharmacy Summit 2019, a panel of experts educated audience members about chronic inflammatory demyelinating polyneuropathy.
FDA Approves Galcanezumab-gnlm for Episodic Cluster Headache
Galcanezumab-gnlm (Emgality, Eli Lilly) is the first calcitonin gene-related peptide antibody approved for both migraine and episodic cluster headache in adults.
FDA Accepts sBLA for Inflammatory Disorder Biologic
Hizentra may treat patients with chronic inflammatory demyelinating polyneuropathy.
Real-World Immunoglobulin Dose Adjustments and Impact on Utilization and Costs
Real-world dose adjustments occurred in patients with primary immunodeficiency who switched from intravenous immunoglobulin to subcutaneous immunoglobulin 20%, with resulting implications for payers, patients, and plasma collection and supply.
Alzheimer's Treatment Study Reports 3 Years With No Decline In Memory And Function At AAIC 2012
The first report of long-term (3-year) stabilization of Alzheimer's disease symptoms with IVIG, including no decline on measures of cognition, memory, daily functioning and mood, was recently reported at the Alzheimer's Association International Conference 2012 in Vancouver.
IVIG and SCIG: A Look at Wellpartner Pharmacy
This home delivery pharmacy focuses in intravenous immune globulin programs to improve care and outcomes for patients.
Specialty Pharmaceuticals: Immunoglobulin Therapy
When patients have immunodeficiency conditions that require immunoglobulin therapy (IVIG), clinicians must consider carefully which IVIG product will have the fewest adverse effects and the highest level of efficacy.
+ Load More